Asano Y - Search Results

1

Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis.

Kuzumi A, Yoshizaki A, Matsuda KM, Kotani H, Norimatsu Y, Fukayama M, Ebata S, Fukasawa T, Yoshizaki-Ogawa A, Asano Y, Morikawa K, Kazoe Y, Mawatari K, Kitamori T, Sato S. Kuzumi A, et al. Among authors: asano y. Nat Commun. 2021 Oct 12;12(1):5947. doi: 10.1038/s41467-021-26099-w. Nat Commun. 2021. PMID: 34642338 Free PMC article.

2

Potential regulatory elements of the constitutive up-regulated alpha2(I) collagen gene in scleroderma dermal fibroblasts.

Jinnin M, Ihn H, Mimura Y, Asano Y, Tamaki K. Jinnin M, et al. Among authors: asano y. Biochem Biophys Res Commun. 2006 May 12;343(3):904-9. doi: 10.1016/j.bbrc.2006.03.037. Epub 2006 Mar 20. Biochem Biophys Res Commun. 2006. PMID: 16564026

3

Future treatments in systemic sclerosis.

Asano Y. Asano Y. J Dermatol. 2010 Jan;37(1):54-70. doi: 10.1111/j.1346-8138.2009.00758.x. J Dermatol. 2010. PMID: 20175840 Review.

4

A case of dermatomyositis with "liver disease associated with rheumatoid diseases" positive for anti-liver-kidney microsome-1 antibody.

Noda S, Asano Y, Tamaki Z, Takekoshi T, Sugaya M, Sato S. Noda S, et al. Among authors: asano y. Clin Rheumatol. 2010 Aug;29(8):941-3. doi: 10.1007/s10067-010-1397-3. Epub 2010 Feb 24. Clin Rheumatol. 2010. PMID: 20179980

5

Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.

Yoshizaki A, Yanaba K, Yoshizaki A, Iwata Y, Komura K, Ogawa F, Takenaka M, Shimizu K, Asano Y, Hasegawa M, Fujimoto M, Sato S. Yoshizaki A, et al. Among authors: asano y. Arthritis Rheum. 2010 Aug;62(8):2476-87. doi: 10.1002/art.27498. Arthritis Rheum. 2010. PMID: 20506342 Free article.

6

The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis.

Asano Y, Bujor AM, Trojanowska M. Asano Y, et al. J Dermatol Sci. 2010 Sep;59(3):153-62. doi: 10.1016/j.jdermsci.2010.06.008. Epub 2010 Jul 3. J Dermatol Sci. 2010. PMID: 20663647 Free PMC article. Review.

7

Serum CCL23 levels are increased in patients with systemic sclerosis.

Yanaba K, Yoshizaki A, Muroi E, Ogawa F, Asano Y, Kadono T, Sato S. Yanaba K, et al. Among authors: asano y. Arch Dermatol Res. 2011 Jan;303(1):29-34. doi: 10.1007/s00403-010-1078-8. Epub 2010 Sep 8. Arch Dermatol Res. 2011. PMID: 20824279

8

Serum levels of soluble CD21 in patients with systemic sclerosis.

Tomita M, Kadono T, Yazawa N, Kawashima T, Tamaki Z, Ashida R, Ohmatsu H, Asano Y, Sugaya M, Kubo M, Ihn H, Tamaki K, Sato S. Tomita M, et al. Among authors: asano y. Rheumatol Int. 2012 Feb;32(2):317-21. doi: 10.1007/s00296-010-1610-3. Epub 2010 Oct 30. Rheumatol Int. 2012. PMID: 21052675

9

Altered dynamics of transforming growth factor β(TGF-β) receptors in scleroderma fibroblasts.

Asano Y, Ihn H, Jinnin M, Tamaki K, Sato S. Asano Y, et al. Ann Rheum Dis. 2011 Feb;70(2):384-7. doi: 10.1136/ard.2009.127811. Epub 2010 Nov 15. Ann Rheum Dis. 2011. PMID: 21081531

10

CCR10 and CCL27 are overexpressed in cutaneous squamous cell carcinoma.

Kai H, Kadono T, Kakinuma T, Tomita M, Ohmatsu H, Asano Y, Tada Y, Sugaya M, Sato S. Kai H, et al. Among authors: asano y. Pathol Res Pract. 2011 Jan 15;207(1):43-8. doi: 10.1016/j.prp.2010.10.007. Epub 2010 Dec 7. Pathol Res Pract. 2011. PMID: 21144674

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,494 results

Search Page